Biotech Values

[St_armands_man]

VSGN - Vasogen's Phase III SIMPADICO Results to be Presented at Late-Breaking Session of the 55th Annual Scientific Session of the American College of Cardiology
2/1/2006 6:01:01 AM

TORONTO, Feb 01, 2006 /PRNewswire-FirstCall via COMTEX/ -- Vasogen Inc. (VSGN), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that the pivotal phase III SIMPADICO trial in peripheral arterial disease (PAD) has been accepted for presentation at a Late- Breaking Clinical Trial session of the 55th Annual Scientific Session of the American College of Cardiology (ACC). The ACC meeting, which is being held in Atlanta from March 11 to 14, 2006, attracts approximately 20,000 cardiovascular professionals from the United States, Canada, and the rest of the world